Literature DB >> 9547165

Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype.

S J Allen1, S H MacGowan, S Tyler, G K Wilcock, A G Robertson, P H Holden, S K Smith, D Dawbarn.   

Abstract

Apolipoprotein E (ApoE) is a potent risk factor for Alzheimer's disease. Since the loss of cholinergic function in Alzheimer's disease is known to occur at an early stage in the disease we have examined this function in normal subjects with an Apoepsilon4 allele to see if the deficit occurs in the absence of Alzheimer pathology or symptoms. We report that brain tissue obtained post-mortem from normal subjects and Alzheimer patients with an Apoepsilon4 allele has a lower cholinergic activity than tissue from those subjects without this allele. This has important significance for the interpretation of the cholinergic deficits found in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9547165     DOI: 10.1016/s0304-3940(97)00872-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice.

Authors:  Jessica A Siegel; Michael J Craytor; Jacob Raber
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

2.  The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease risk.

Authors:  Robert D Nebes; Bruce G Pollock; Subashan Perera; Edythe M Halligan; Judith A Saxton
Journal:  Am J Geriatr Pharmacother       Date:  2012-04-24

Review 3.  Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.

Authors:  S Chatterjee; S E Bartlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

4.  Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons.

Authors:  G O'Meara; U Coumis; S Y Ma; J Kehr; S Mahoney; A Bacon; S J Allen; F Holmes; U Kahl; F H Wang; I R Kearns; S Ove-Ogren; D Dawbarn; E J Mufson; C Davies; G Dawson; D Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease.

Authors:  Marina Del Prete; Simona Spaccavento; Angela Craca; Pietro Fiore; Paola Angelelli
Journal:  Neurol Sci       Date:  2009-07-10       Impact factor: 3.307

6.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

7.  Attentional performance, impulsivity, and related neurotransmitter systems in apoE2, apoE3, and apoE4 female transgenic mice.

Authors:  Ingrid Reverte; Fiona Peris-Sampedro; Pia Basaure; Leticia Campa; Cristina Suñol; Margarita Moreno; José Luis Domingo; Maria Teresa Colomina
Journal:  Psychopharmacology (Berl)       Date:  2016-01       Impact factor: 4.530

8.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

Review 9.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 10.  APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis.

Authors:  Ying Liu; Jin-Tai Yu; Hui-Fu Wang; Pei-Ran Han; Chen-Chen Tan; Chong Wang; Xiang-Fei Meng; Shannon L Risacher; Andrew J Saykin; Lan Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-16       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.